ALGN vs VVOS: Align Technology's Stability Stands Out Against Vivos Therapeutics' -90% Slide
Key Takeaways
- ALGN is a large-cap, profitable medical device leader (Invisalign clear aligners and iTero scanners), while VVOS is a micro-cap, unprofitable sleep apnea device company in a strategic pivot.
- The two names differ sharply in scale, with Align Technology near a $10 billion market value and Vivos Therapeutics around a low-single-digit million-dollar market capitalization.
- Align generates roughly $4 billion in annual revenue with expanding margins; Vivos reported about $20.9 million in trailing revenue and a net loss of more than $25 million.
- Relative performance has diverged: ALGN has pulled back modestly in recent weeks, while VVOS shares have fallen more than 90% over the past year amid dilution and listing concerns.
- Align faces weakening consumer-demand signals in its imaging and systems business, while Vivos contends with balance-sheet repair and a Nasdaq minimum bid price compliance notice.
Setting the Scene
This comparison brings together two healthcare companies that operate in medical devices but could hardly be more different: Align Technology, with its established orthodontic and dental-imaging franchise, and Vivos Therapeutics, a small-cap player developing oral appliances for obstructive sleep apnea. Growth-oriented investors may appreciate Align's profitability and scale, while those comfortable with higher risk might see Vivos as a speculative turnaround play. Looking at recent market moves, performance trends, and the fundamentals underneath helps clarify where each sits and what the risk-reward balance looks like right now.
ALGN: Overview and Recent Moves
ALGN, Align Technology, designs and manufactures the Invisalign clear aligner system along with iTero intraoral scanners. In the latest quarter the company posted non-GAAP EPS of $2.64, up 6% from a year earlier, on revenue near $1.06 billion. Record Clear Aligner shipments and solid double-digit growth internationally helped drive the numbers, although the Imaging Systems and CAD/CAM Services segment slipped about 10.8% as capital-equipment demand softened and the mix shifted toward lower-priced options and leasing.
Sentiment has eased a bit lately. Evercore ISI moved the stock to In Line from Outperform and trimmed its price target, pointing to a softer consumer environment and slower demand indicators. Shares have eased roughly 9% over the past month, yet the consensus rating remains a Buy with an average target near $199. Management kept full-year revenue growth guidance at 3% to 4%, expanded its share-repurchase program, and entered a cooperation agreement with an activist investor. These steps point to a large-cap franchise that is stable yet growing more slowly as it navigates mixed signals from end markets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
VVOS: Overview and Recent Moves
VVOS, Vivos Therapeutics, develops and sells oral appliance therapies for obstructive sleep apnea, including its FDA-cleared CARE devices. The company is shifting its model away from enrolling independent dentists and toward owning and operating sleep testing and treatment centers, a move meant to boost revenue but one that demands sizable upfront spending.
The transition has pressured results so far. Second-quarter revenue climbed to about $5.15 million from $3.82 million a year earlier, yet the company still recorded a net loss. In the first quarter the net loss widened to $7.8 million, with cash around $2.1 million and a stockholders' equity deficit. Management has swapped outstanding debt for common shares to cut principal, and the company received a Nasdaq notice that its stock no longer meets the $1.00 minimum bid price requirement. Shares have dropped more than 90% over the past year and sit near their 52-week low, reflecting dilution and continued financing pressure, though the handful of covering analysts still carry a consensus price target well above the current level.
Side-by-Side Comparison
The most obvious difference between the two is financial staying power. Align Technology stays consistently profitable, holds more than $1 billion in cash, and finances its own growth and buybacks. Vivos Therapeutics remains unprofitable, runs with a thin cash position, and has leaned on debt-for-equity swaps and follow-on offerings to keep operations going. On the growth side, Align relies on wider global adoption of aligners plus momentum in teen and pediatric patients, while Vivos is counting on its integrated sleep-center network to expand OSA treatment reach.
Risk profiles also stand apart. Align's main concerns are macro-related, such as softer consumer spending and pricing pressure in scanners and certain international markets. Vivos faces more fundamental risks, including a sub-$1.00 share price, possible delisting, and ongoing shareholder dilution. Market views mirror the gap: Align draws broad institutional coverage and a Buy consensus, whereas Vivos sees thin coverage and extreme volatility. In short, Align delivers scale and steadiness with slower growth, while Vivos presents a speculative turnaround story with a much higher chance of capital loss.
AI-Assisted Perspective
From what I see in the data on trend consistency, financial stability, catalysts, and relative positioning, an AI-driven assessment would likely lean toward ALGN over VVOS in the current setting. Align shows a steadier trend structure, positive earnings, a solid balance sheet, and clear catalysts from upcoming results plus its capital-return program, even with some near-term demand softness. Vivos, on the other hand, carries higher volatility, continued dilution, and a weaker liquidity position that tends to lower confidence in trend-following models. This view is probabilistic, based on measurable traits today rather than any prediction of future returns.
Using Tickeron AI Trading Bots for Strategy Testing
When comparing names like these, I often review automated strategies through Tickeron’s marketplace of AI trading bots. The Trending AI Robots section surfaces bots whose recent signals, win rates, and consistency best match current conditions, offering a practical way to evaluate approaches across different risk profiles and timeframes without having to build everything from scratch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
ALGN's Indicator enters downward trend
The Aroon Indicator for ALGN entered a downward trend on October 08, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 244 similar instances where the Aroon Indicator formed such a pattern. In 194 of the 244 cases the stock moved lower. This puts the odds of a downward move at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALGN as a result. In 59 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The 50-day moving average for ALGN moved below the 200-day moving average on September 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALGN's RSI Indicator exited the oversold zone, 28 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ALGN just turned positive on October 08, 2026. Looking at past instances where ALGN's MACD turned positive, the stock continued to rise in 30 of 43 cases over the following month. The odds of a continued upward trend are 70%.
Following a +1.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGN advanced for three days, in 194 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
ALGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.434) is normal, around the industry mean (5.011). P/E Ratio (25.174) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.611) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.612) is also within normal values, averaging (56.074).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. ALGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of the invisalign system for treating malocclusion
Industry PharmaceuticalsOther
Advertisement